EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma

Juan Chipollini, Mounsif Azizi, Charles C Peyton, Dominic H Tang, Jasreman Dhillon, Philippe E Spiess

Journal of Kidney Cancer and VHL · 13.10.2018 · 5 (4) · 6-13

DOI: 10.15586/jkcvhl.2018.107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Kidney Cancer and VHL, online erschienen am 13.10.2018. Verfasst von Juan Chipollini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan–Meier method. Median age was 58 years and median follow-up was 40 months. Non-ccRCC subtypes included sarcomatoid (n = 9), rhabdoid (n = 6), medullary (n = 2), Xp11.2 translocation (n = 2), collecting duct (n = 1), papillary type I (n = 11), and papillary type II (n = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of non-ccRCC cases and was associated with adverse histopathologic features. Expression of biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions and follow-up strategies.

Schlagwörter

Stichwörter der Autor:innen

non-clear cell renal cell carcinomaprognosisprogrammed death ligand-1renal cell cancertumor marker

Autor:innen und Institutionen

  • Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Zitieren

APA

Chipollini, J., Azizi, M., Peyton, C. C., Tang, D. H., Dhillon, J., & Spiess, P. E. (2018). Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 5(4), 6-13. https://doi.org/10.15586/jkcvhl.2018.107

Vancouver

Chipollini J, Azizi M, Peyton CC, Tang DH, Dhillon J, Spiess PE. Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer and VHL. 2018;5(4):6-13. doi:10.15586/jkcvhl.2018.107

BibTeX
@article{Chipollini2018,
  author = {Chipollini, Juan and Azizi, Mounsif and Peyton, Charles C and Tang, Dominic H and Dhillon, Jasreman and Spiess, Philippe E},
  title = {Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma},
  journal = {Journal of Kidney Cancer and VHL},
  year = {2018},
  volume = {5},
  number = {4},
  pages = {6--13},
  doi = {10.15586/jkcvhl.2018.107}
}
Kostenlos starten →